Physician profile
Stuart D D Kaplan
NPI 1316940984
$29,143.75
in general payments reported to CMS, 2019-2025
42 companies · $4,475 in 2025
The $4,475 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,710 · 2020: $3,454 · 2021: $3,881 · 2022: $4,520 · 2023: $4,523 · 2024: $4,581 · 2025: $4,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,220.39 |
| Education | $358.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,146.81 | 2019-2025 | Evenity, Tavneos, Prolia |
| Abbvie INC. | $4,317.41 | 2019-2025 | |
| Janssen Biotech, INC. | $3,796.96 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $2,059.92 | 2019-2024 | Taltz, Zepbound, Olumiant |
| Pfizer INC. | $1,843.74 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,688.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,583.18 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $1,190.85 | 2020-2025 | Acthar |
| Ucb, INC. | $1,167.09 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $1,151.35 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $720.71 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $677.41 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $555.98 | 2019-2025 | Orencia |
| Genentech USA, INC. | $478.97 | 2019-2024 | Actemra, Rituxan |
| Mallinckrodt Enterprises LLC | $355.89 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart D Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.